Antiviral use of cationic surfactant

Details Antiviral use of cationic surfactant Antiviral use of cationic surfactant

A - Human Necessities

61

K

A61K 31/16 (2006.01) A61P 31/12 (2006.01)

Patent

CA 2658446

Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the protection against the growth of the microorganisms. The cationic surfactants of this type are also effective against virus infections. Addition of LAE to cultures of Herpes virus type 1 Vaccinia virus and bovine parainfluenzae 3 virus leads to nearly complete reduction of the virus organisms in these cultures, such effects being observed after 5 and 60 minutes.

tensio-actifs cationiques dérivés de la condensation d'acides gras et d'aminoacides dibasiques estérifiés, du type acide laurique et arginine, en particulier éthyl ester de lauramide de monohydrochlorure d'arginine (LAE), que l'on peut utiliser pour la protection contre la croissance des micro-organismes. les tensioactifs cationiques de ce type sont également efficaces contre les infections virales. L'adjonction de LAE à des cultures d'herpès virus de type 1 de vaccinia virus et de virus parainfluenza bovin 3 permet une réduction presque totale des organismes viraux dans ces cultures, de tels effets étant observés après une durée comprise entre 5 et 60 minutes.

Affiliated with

Also associated with

Rating

Antiviral use of cationic surfactant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral use of cationic surfactant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral use of cationic surfactant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1961826